CN114746430B - 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 - Google Patents
治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物Info
- Publication number
- CN114746430B CN114746430B CN202080084283.6A CN202080084283A CN114746430B CN 114746430 B CN114746430 B CN 114746430B CN 202080084283 A CN202080084283 A CN 202080084283A CN 114746430 B CN114746430 B CN 114746430B
- Authority
- CN
- China
- Prior art keywords
- compound
- och
- independently
- ocf
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
- C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202610035916.3A CN121949079A (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911069P | 2019-10-04 | 2019-10-04 | |
| US62/911,069 | 2019-10-04 | ||
| US202062991525P | 2020-03-18 | 2020-03-18 | |
| US62/991,525 | 2020-03-18 | ||
| PCT/US2020/054107 WO2021067836A1 (en) | 2019-10-04 | 2020-10-02 | Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202610035916.3A Division CN121949079A (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114746430A CN114746430A (zh) | 2022-07-12 |
| CN114746430B true CN114746430B (zh) | 2026-01-30 |
Family
ID=72964859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080084283.6A Active CN114746430B (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 |
| CN202610035916.3A Pending CN121949079A (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202610035916.3A Pending CN121949079A (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11584728B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4038076A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2022551270A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220078644A (cg-RX-API-DMAC10.html) |
| CN (2) | CN114746430B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2020358970C1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3156499A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL291898B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021067836A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291898B1 (en) * | 2019-10-04 | 2026-06-01 | Stealth Biotherapeutics Inc | Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders |
| AU2022291142A1 (en) * | 2021-06-10 | 2023-12-21 | Stealth Biotherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| AU2024300048A1 (en) * | 2023-07-21 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
| AU2024377199A1 (en) * | 2023-11-09 | 2026-05-21 | Stealth Biotherapeutics Inc. | Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
| WO2026020091A1 (en) * | 2024-07-19 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compounds, compositions, formulations and uses for addressing mitochondrial disease resulting from nuclear dna mutations |
| WO2026050137A1 (en) * | 2024-08-26 | 2026-03-05 | Stealth Biotherapeutics Inc. | A combination therapy for the treatment of friedreich's ataxia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332534A1 (en) * | 2006-02-22 | 2011-06-15 | Edison Pharmaceuticals, Inc. | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| WO2012022467A2 (en) * | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| WO2017087795A1 (en) * | 2015-11-19 | 2017-05-26 | Concert Pharmaceuticals, Inc. | Deuterated epi-743 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| CA2272971C (en) | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) * | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NO2470168T3 (cg-RX-API-DMAC10.html) | 2009-08-26 | 2018-06-30 | ||
| US20130345312A1 (en) | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| HRP20161407T1 (hr) | 2010-08-16 | 2016-12-02 | Santhera Pharmaceuticals (Schweiz) Ag | Derivati benzokinona za liječenje mitohondrijskih bolesti oka |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| KR102137450B1 (ko) * | 2012-07-12 | 2020-07-27 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| JP6367211B2 (ja) | 2012-11-16 | 2018-08-01 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体 |
| JP2016515526A (ja) * | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| WO2018191732A1 (en) | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| IL305687B2 (en) | 2017-12-15 | 2024-12-01 | Stealth Biotherapeutics Inc | Mitochondria-targeting peptides |
| IL291898B1 (en) * | 2019-10-04 | 2026-06-01 | Stealth Biotherapeutics Inc | Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders |
-
2020
- 2020-10-01 IL IL291898A patent/IL291898B1/en unknown
- 2020-10-02 IL IL328635A patent/IL328635A/en unknown
- 2020-10-02 JP JP2022520475A patent/JP2022551270A/ja active Pending
- 2020-10-02 US US17/062,339 patent/US11584728B2/en active Active
- 2020-10-02 CN CN202080084283.6A patent/CN114746430B/zh active Active
- 2020-10-02 EP EP20793924.0A patent/EP4038076A1/en active Pending
- 2020-10-02 CN CN202610035916.3A patent/CN121949079A/zh active Pending
- 2020-10-02 WO PCT/US2020/054107 patent/WO2021067836A1/en not_active Ceased
- 2020-10-02 CA CA3156499A patent/CA3156499A1/en active Pending
- 2020-10-02 AU AU2020358970A patent/AU2020358970C1/en active Active
- 2020-10-02 KR KR1020227014887A patent/KR20220078644A/ko active Pending
-
2022
- 2022-12-23 US US18/087,890 patent/US12049455B2/en active Active
-
2024
- 2024-07-02 US US18/761,854 patent/US20240400529A1/en active Pending
- 2024-07-02 US US18/761,782 patent/US20240368098A1/en active Pending
-
2025
- 2025-07-03 JP JP2025113088A patent/JP2025164962A/ja active Pending
-
2026
- 2026-05-02 AU AU2026203365A patent/AU2026203365A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332534A1 (en) * | 2006-02-22 | 2011-06-15 | Edison Pharmaceuticals, Inc. | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| WO2012022467A2 (en) * | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| WO2017087795A1 (en) * | 2015-11-19 | 2017-05-26 | Concert Pharmaceuticals, Inc. | Deuterated epi-743 |
Non-Patent Citations (4)
| Title |
|---|
| Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity;Hattori Y et al.;Bioorganic and Medicinal Chemistry Letters;20091211;第20卷(第3期);第1063-1064页 * |
| Construction of Bridged-Ring-Fused Naphthalenone Derivatives Through an Unexpected Zn(OTf)2-Catalyzed Cascade Transformation;Chandraiah Lagishetti et al.;Organic Letters;20190620;第21卷(第13期);第5301-5304页 * |
| Synthesis of the Amido Hydroquinone Core and the C10-C15 Fragment.Synlett.2012,第19卷第2845-2849页. * |
| Zhao, GL et al..Toward a Total Synthesis of Divergolide A * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021067836A1 (en) | 2021-04-08 |
| AU2020358970B2 (en) | 2026-02-05 |
| US11584728B2 (en) | 2023-02-21 |
| KR20220078644A (ko) | 2022-06-10 |
| AU2020358970C1 (en) | 2026-08-06 |
| US20210206736A1 (en) | 2021-07-08 |
| IL328635A (en) | 2026-07-01 |
| CA3156499A1 (en) | 2021-04-08 |
| CN114746430A (zh) | 2022-07-12 |
| CN121949079A (zh) | 2026-05-01 |
| JP2025164962A (ja) | 2025-10-31 |
| JP2022551270A (ja) | 2022-12-08 |
| US20240368098A1 (en) | 2024-11-07 |
| IL291898B1 (en) | 2026-06-01 |
| US20230303506A1 (en) | 2023-09-28 |
| EP4038076A1 (en) | 2022-08-10 |
| AU2026203365A1 (en) | 2026-07-23 |
| US12049455B2 (en) | 2024-07-30 |
| US20240400529A1 (en) | 2024-12-05 |
| IL291898A (en) | 2022-06-01 |
| AU2020358970A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN121949079A (zh) | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 | |
| CN115996916B (zh) | 用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法 | |
| CA3222132A1 (en) | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia | |
| JP2021523934A (ja) | ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物 | |
| EP2814479B1 (en) | Methods of treating amyotrophic lateral sclerosis | |
| CN114728920B (zh) | 一种沃替西汀前药及其应用 | |
| WO2023272571A1 (zh) | 2,3-环氧丁二酰衍生物的医药用途 | |
| WO2024239762A1 (zh) | 磷酸二酯酶4抑制剂、其药物组合物及其应用 | |
| WO2015154716A1 (zh) | 菲罗啉膦酸类衍生物及其制备方法和应用 | |
| CN113387909B (zh) | 2,3-环氧丁二酰衍生物的医药用途 | |
| EP3641756A1 (en) | Tricyclic compounds as cyp1 inhibitors | |
| CN118382435A (zh) | 12/15-脂氧合酶抑制剂 | |
| HK40088188B (en) | Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia | |
| JP2024520758A (ja) | Ttbk1の阻害剤 | |
| HK40088188A (en) | Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia | |
| IT202400002560A1 (it) | Inibitori della proteina rock per uso nel trattamento della fibrosi polmonare | |
| WO2020028552A1 (en) | Methods of activating microglial cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |